Upcoming Events
Log In
Pricing
Free Trial

Wk 4, Case 5 - Review

HIDE
PrevNext

0:04

Patient presenting with extensive metastatic to liver,

0:08

which is very common for the small bowel

0:10

because even they, a lot of times they do, um,

0:13

CT enterography, um,

0:18

they, we can, they can't find the small bowel

0:22

primary site.

0:24

It's usually very small.

0:26

Small bowel is very hard to assess, of course,

0:28

because the extensive disease in the

0:30

liver, the liver look black.

0:31

No matter how much I decrease the intensity.

0:34

See how the parenchyma is not as black,

0:36

but actually all this is metastatic disease in the liver.

0:41

Right? And let me,

0:45

of course there's medicinal lymph nodes you can see here.

0:51

And there's also super, I remember

0:53

because I increased the intensity dramatically.

0:55

See there's here it's hot, but because which is this here,

0:59

because I, I decreased the intensity dramatically.

1:01

It just, I tweaked down.

1:03

So I go down, which is the pattern we talked about

1:06

last time, right?

1:07

GI cancers, track the,

1:11

and then goes, jumps to the lift, lift the,

1:13

it's called the black house node.

1:15

It's jump there, it's known it's a pattern.

1:17

Uh, but now what's important is

1:22

to look at here.

1:23

Here's the mr like I told you, look for them.

1:26

Here's the mesenteric. See node.

1:29

Go to the mesenteric calcified mesenteric node.

1:32

This is a, this is a typical pattern of for the, um,

1:38

med gut, which is what, which is the primary,

1:41

which is the small valve.

1:42

It's called me gut, right?

1:44

So look at your dominant enteric mass,

1:49

which is this one here, which is this one here, right?

1:53

And then look close to it.

1:55

You'll find another focus that is fusing

1:57

to a small bowel here.

1:58

Look guys, the focus fusing to the small bowel.

2:01

This is always the case.

2:04

See, I'm scrolling up

2:09

and down to show you that this is actually not

2:10

another mis enteric.

2:11

No, this is really a small l

2:15

This is the focus here and this is the ct.

2:18

If you wanna look at the cts up

2:20

and down, it's a small valve.

2:22

So here's your primary side.

2:25

This is the primary small valve in the consumer.

2:28

This is the metastatic. Um,

2:31

and I can put, uh,

2:35

here, this is a plus.

2:37

I, I don't know if you can see it, but there's a plus.

2:40

Did it go away? Yeah,

2:44

there's a plus here.

2:45

Do you see it here? Which is here.

2:49

And you can see it here in the map so I can show it here.

2:52

You see, here's the primary

2:54

and here's the, here's the me notes,

2:58

Right?

3:02

I wanna tell you that more than 99%

3:04

of the time when they send us a patient

3:07

with unknown primary, which is al almost always a al,

3:11

almost always a small bowel primary,

3:14

we can find the primary site for them.

3:16

Why is it important? Um, like you look at this case

3:20

and there's extensive metastatic disease to deliver.

3:22

This is not oleum metastatic,

3:23

like we talked about last time.

3:25

It's extensive metastatic. So why is it important?

3:29

Um, it's important because small bowel, uh, um, lesions,

3:33

eventually it will obstruct right to keep growing, growing

3:37

to till one.

3:39

At one point this small bowel is gonna obstruct.

3:43

Surgeons prefer to get in

3:45

and resected in a,

3:48

a nice quiet abdomen rather than this patient coming

3:51

to the emergency room with small bowel obstruction

3:55

and having to get in to, to an angry abdomen, messed up

4:00

with small bowel obstruction looking for a mess, right?

4:06

So this is why it's important for us to find it for them

4:09

and show them where is the primary side

4:10

so they can get in and get it out.

4:13

Uh, now, then later, this is why it's important

4:17

to find the primary side.

4:20

Um, so, so synthetic node, the static lymph node,

4:24

lymph node as I showed you, extends

4:28

liver for this patient.

4:31

Extensive, right?

4:37

Typical, um, small bowel,

4:41

like I said, synthetic is the typical plus

4:46

or minus Nia for, for the small bowel liver, of course,

4:50

always, almost always.

4:52

And as long as there is like slight disease, it's always,

4:55

almost always, um, they survive for a long time.

4:59

Uh, but unfortunately the liver meds, uh, many, many

5:02

of them have of carcinoid syndrome symptoms.

5:04

And this is what they really suffer from.

Report

Please note: Items with dashed lines (--) are information withheld as it is not relevant for you to arrive at the correct findings and impression for the report and/or it was withheld for privacy information. The items were left in to show you the typical information documented in a PET report.

Clinical Indication:
Male with well-differentiated grade 2 metastatic neuroendocrine tumor to the liver, kidney and bladder of unknown primary. Currently treated with octreotide.

Technique:
Preparation: On Somatostatin Analogue Therapy.
Radiopharmaceutical: _ mCi of Cu-64 dotatate (DETECTNET), a somatostatin analogue (SSA), administered IV at ---at ---. Incubation interval: _ minutes.
Oral contrast: ----.
Positioning: Arms raised.
PET/CT scanner: Siemens Biograph 40 mCT.
PET/CT acquisition: Vertex-to-mid-thighs.
Standardized uptake value (SUV): Corrected for ---.
CT: Low-dose, non-breath-hold, without intravenous contrast.
TOTAL DLP (Dose Length Product): ______mGy.cm.

Comparison/Correlation:
--

Findings:
Technical quality: Diagnostic.
Measurements: Unless otherwise specified, all SUVs refer to maximum value in the target.
Reference: mean SUV liver: -----
CT linear measurements performed on axial images.


Head and Neck:
Mildly SSA-avid nonenlarged right supraclavicular lymph node measuring 5 mm, max SUV 4.7.
No other suspicious cervical adenopathy.
Unremarkable thyroid.


Chest:
Multiple intensely SSA-avid mediastinal lymph nodes. Examples are:

A right upper paratracheal lymph node measures 14 mm, max SUV 70.8
Lower paratracheal lymph node at the bifurcation measures 17 mm, max SUV 45.4

Moderate centrilobular emphysema.
No suspicious lung nodule.
Coronary artery calcifications. Cardiac stent.


Abdomen and Pelvis:
Intensely SSA avid mesenteric soft tissue mass with coarse calcification located within the right small bowel mesentery with adjacent mesenteric stranding measuring 2.6 x 2.2 cm, max SUV 32.3.
Adjacent to this mesenteric mass, there is focal intense increased uptake within a thickened loop of small bowel, likely ileal, max SUV 27.2, likely representing the primary small bowel site.
Innumerable intensely SSA-avid metastatic lesions throughout the liver. Examples are:

The largest is located within the inferior right hemiliver measuring 8.0 x 9.0 cm, max SUV 69.5
A lesion in the hepatic dome measures 2.9 x 2.6 cm, max SUV 36.5

Enlarged, intensely SSA-avid porta hepatis lymph node measuring 16mm, max SUV 40.3.
Multiple small, SSA-avid para-aortic lymph nodes. For example, a 5 mm node with max SUV 8.4.
No suspicious SSA-avid foci in the kidneys.
Unremarkable spleen, adrenal glands, and pancreas.
Bilateral nonobstructive nephrolithiasis. No hydronephrosis.
Subcentimeter hyperdensity arising from the left interpolar region, too small to characterize.
Diffuse colonic diverticulosis without evidence of acute inflammation. Remainder of the small bowel is normal in caliber.
Diffuse bladder wall thickening and small diverticula.
Mildly enlarged prostate with coarse calcifications.


Skeleton and Soft Tissues:
No SSA-avid lesions in the osseous structures.
No aggressive lytic or sclerotic lesion.
Mild soft tissue thickening of the bilateral inguinal canals, left greater than right, with mild SSA uptake, max SUV 7.0, likely inflammatory.
Degenerative changes of the spine.

Impression:
1. SSA-avid metastatic small bowel mesenteric mass with coarse calcification.
2. Adjacent focal intense SSA uptake fusing to a thickened loop of small bowel, ileal, consistent with primary neuroendocrine tumor site.
3. Intensely SSA avid metastatic porta hepatis, retroperitoneal, mediastinal, and right supraclavicular lymphadenopathy.
4. Innumerable intensely SSA-avid metastatic hepatic lesions.

Case Discussion

Faculty

Riham El Khouli, MD

Associate Professor of Radiology, Chief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics

University of Kentucky

Michael F. Shriver, MD

Director of Nuclear Medicine

Proscan-NCH Imaging

Tags

PET/CT DOTATATE

PET

Nuclear Medicine

Neuroendocrine

CT